Rate of severe exacerbations, healthcare resource utilisation and clinical outcomes in patients with COPD in low-income and middle-income countries: results from the EXACOS International Study

Author:

Athanazio Rodrigo AbensurORCID,Bernal Villada Laura,Avdeev Sergey N,Wang Hao-Chien,Ramírez-Venegas Alejandra,Sivori Martín,Dreyse Jorge,Pacheco Manuel,Man Sin Kit,Noriega-Aguirre Lorena,Farouk Hisham

Abstract

IntroductionTheEXAcerbations ofChronic obstructive lung disease (COPD) and theirOutcomeS(EXACOS) International Study aimed to quantify the rate of severe exacerbations and examine healthcare resource utilisation (HCRU) and clinical outcomes in patients with COPD from low-income and middle-income countries.MethodsEXACOS International was an observational, cross-sectional study with retrospective data collection from medical records for a period of up to 5 years. Data were collected from 12 countries: Argentina, Brazil, Chile, Colombia, Costa Rica, Dominican Republic, Guatemala, Hong Kong, Mexico, Panama, Russia and Taiwan. The study population comprised patients ≥40 years of age with COPD. Outcomes/variables included the prevalence of severe exacerbations, the annual rate of severe exacerbations and time between severe exacerbations; change in lung function over time (measured by the forced expiratory volume in 1 s (FEV1)); peripheral blood eosinophil counts (BECs) and the prevalence of comorbidities; treatment patterns; and HCRU.ResultsIn total, 1702 patients were included in the study. The study population had a mean age of 69.7 years, with 69.4% males, and a mean body mass index of 26.4 kg/m2. The mean annual prevalence of severe exacerbations was 20.1%, and 48.4% of patients experienced ≥1 severe exacerbation during the 5-year study period. As the number of severe exacerbations increased, the interval between successive exacerbations decreased. A statistically significant decrease in mean (SD) FEV1from baseline to post-baseline was observed in patients with ≥1 severe exacerbation (1.23 (0.51) to 1.13 (0.52) L; p=0.0000). Mean BEC was 0.198 x109cells/L, with 64.7% of patients having a BEC ≥0.1 x109 cells/L and 21.3% having a BEC ≥0.3 x109 cells/L. The most common comorbidity was hypertension (58.3%). An increasing number of severe exacerbations per year was associated with greater HCRU.DiscussionThe findings presented here indicate that effective treatment strategies to prevent severe exacerbations in patients with COPD remain a significant unmet need in low-income and middle-income countries.

Funder

AstraZeneca

Publisher

BMJ

Reference114 articles.

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD) . Global strategy for prevention, diagnosis and management of COPD: 2024 report. Available: https://goldcopd.org/2024-gold-report/ [Accessed 14 Jan 2024].

2. The current landscape of COPD-related clinical trials registered on the world health organization's International clinical trials Registry platform: a comprehensive analysis of study characteristics and publication status;Xu;Chronic Obstr Pulm Dis,2023

3. Epidemiology of Chronic Obstructive Pulmonary Disease

4. Wood smoke exposure and risk of chronic obstructive pulmonary disease

5. Exposure to biomass smoke and chronic airway disease in Mexican women. A case-control study.

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. A clinician’s guide to single vs multiple inhaler therapy for COPD;Expert Review of Respiratory Medicine;2024-07-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3